Lucely del Carmen Cetina-Pérez

Dr. Lucely del Carmen Cetina-Pérez

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2021 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
JLJulissa Luvián-Morales
Julissa Luvián-Morales
FVFrancisco Omar Varela-Castillo
Francisco Omar Varela-Castillo
LFLaura Flores-Cisneros
Laura Flores-Cisneros
LCLucely del Carmen Cetina-Pérez
Lucely del Carmen Cetina-Pérez
DCDenisse Castro-Eguiluz
Denisse Castro-Eguiluz
Chronic diseases are responsible for approximately 71% global deaths. These are characterized by chronic low-grade inflammation and metabolic alterations. “Functional foods” have been attributed with anti-inflammatory properties, demonstrated in cell lines and murine models; however, studies in humans are inconclusive. The purpose of this systematic review is to identify clinical trials that analyzed changes in inflammatory and metabolic mediators, in response to consumption of specific functional foods. A total of 3581 trials were screened and 88 were included for this review. Foods identified to regulate inflammation included cranberries, grapes, pomegranate, strawberries, wheat, whole grain products, low fat dairy products, yogurt, green tea, cardamom, turmeric, soy foods, almonds, chia seeds, flaxseed, pistachios, algae oil, flaxseed oil and grape seed oil. Clinical trials that focus on a dietary pattern rich in functional foods are necessary to explore if the additive effect of these foods lead to more clinically relevant outcomes.

1 April 2019 in Journal of Human Nutrition and Dietetics
Verified
Journal Article
Closed access
PDF file
MSM. Sánchez
M. Sánchez
DCDenisse Castro-Eguiluz
Denisse Castro-Eguiluz
JLJ. Luvián‐Morales
J. Luvián‐Morales
RJR. Jiménez‐Lima
R. Jiménez‐Lima
JAJ. L. Aguilar‐Ponce
J. L. Aguilar‐Ponce
LCLucely del Carmen Cetina-Pérez
Lucely del Carmen Cetina-Pérez

2 June 2025 in Annals of Oncology
Verified
Journal Article
Open access
JMJ. Mayadev
J. Mayadev
JLJ.C. Vázquez Limón
J.C. Vázquez Limón
FGF.J. Ramírez Godinez
F.J. Ramírez Godinez
MLM. Leiva
M. Leiva
LCLucely del Carmen Cetina-Pérez
Lucely del Carmen Cetina-Pérez
BMB.J. Monk
B.J. Monk
After chemoradiotherapy (CRT), 30%-50% of patients with locally advanced cervical cancer (LACC) relapse, highlighting the unmet need for prognostic biomarkers. In the global randomized CALLA trial (NCT03830866), the addition of durvalumab during and after CRT did not significantly improve progression-free survival (PFS) in a biomarker-unselected intent-to-treat population. We analyzed the association of ultrasensitive circulating tumor DNA (ctDNA) and circulating human papillomavirus (cHPV) DNA detection with relapse and survival in the largest dataset in LACC to date. In CALLA, adult women with stage IB2-IIB node-positive or IIIA-IVA any node-status LACC were randomized 1 : 1 to receive durvalumab + CRT or CRT alone. The NeXT Personal® (Personalis) ultrasensitive tumor-informed assay with up to 1800 patient-specific variants was used for ctDNA and cHPV DNA analysis at baseline, cycle 3 day 1 (C3D1, post-CRT), and C6D1 (3 months post-CRT). Correlations were analyzed between ctDNA/cHPV DNA detection and outcomes [PFS, overall survival (OS)]. ctDNA was detected in 98.9% (183/185) of baseline samples, with no difference between treatment arms. Detection levels of ctDNA were predictive of disease progression and survival at baseline: hazard ratios (95% confidence intervals) comparing PFS and OS, respectively, in the ctDNA less than median versus ctDNA greater than median subgroups were 0.61 (0.28-1.35) and 0.55 (0.23-1.35) with durvalumab + CRT, and 0.49 (0.26-0.95) and 0.65 (0.33-1.28) with CRT. Post-treatment trends were similar and independent of stage or lymph node status. ctDNA detection at C3D1 occurred a median of 164 days (95% confidence interval 85-250) days before clinical progression. Baseline cHPV DNA levels were similar but were only predictive following treatment. This study demonstrates the potential utility of ultrasensitive detection of ctDNA as a predictive and prognostic marker of disease progression and OS in LACC independent of disease stage.

27 February 2022 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
APAlejandra Rocío Pérez-Martín
Alejandra Rocío Pérez-Martín
DCDenisse Castro-Eguiluz
Denisse Castro-Eguiluz
LCLucely del Carmen Cetina-Pérez
Lucely del Carmen Cetina-Pérez
YVYadira Velasco-Torres
Yadira Velasco-Torres
ABAntonio Bahena-González
Antonio Bahena-González
DGDolores Gallardo-Rincón
Dolores Gallardo-Rincón
Endometrial cancer is the second gynecological cancer with the highest global incidence. Among many associated risk factors, Among the risk factors, metabolic syndrome is an important and preventable one. It comprises a group of conditions that often occur together: central adiposity, hyperglycemia, arterial hypertension, and atherogenic dyslipidemia. This review aimed to describe the epidemiological and biological relationship between metabolic syndrome and endometrial cancer, focusing on the role of lifestyle in prevention. A literature search was carried out in the PubMed database. 4824 publications were screened, and 123 were included for this review. The association between metabolic syndrome and endometrial cancer has been described. Chronic adipose tissue inflammation and insulin resistance are involved in the development of obesity, particularly visceral adiposity. These changes promote the ideal environment for the development of endometrial cancer. Strategies based on lifestyle modifications may be effective for the prevention of metabolic syndrome and consequently endometrial cancer. Some of these modifications include adopting a diet rich in fruits, vegetables, whole grains, and legumes, depending to the accessibility of these foods for each region. Avoiding ultra-processed foods and increasing daily physical activity were also some suggested modifications. We propose that women be screened for metabolic syndrome to establish early treatment and to possibly prevent endometrial cancer. Clinical trials designed to prove the effect of lifestyle modifications on the prevention of endometrial cancer are needed.

1 April 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
TGTatiana Galicia-Carmona
Tatiana Galicia-Carmona
EAEder Arango-Bravo
Eder Arango-Bravo
JSJuan a Serrano-Olvera
Juan a Serrano-Olvera
CTCelia Flores-De La Torre
Celia Flores-De La Torre
ICIvan Cruz-Esquivel
Ivan Cruz-Esquivel
LCLucely del Carmen Cetina-Pérez
Lucely del Carmen Cetina-Pérez
Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated Listeria monocytogenes-listeriolysin O (Lm-LLO), designed by biological engineering to secrete an antigen-adjuvant fusion protein, composed of a truncated fragment of LLO fused to HPV. The proposed mechanism of action is that Lm-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I–II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.

17 June 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BVBlanca Vazquez
Blanca Vazquez
MGMariano Salvador Rojas García
Mariano Salvador Rojas García
JEJOCELYN ISABEL RODRIGUEZ ESQUIVEL
JOCELYN ISABEL RODRIGUEZ ESQUIVEL
JMJaneth Marquez-Acosta
Janeth Marquez-Acosta
CACarlos E. Aranda-Flores
Carlos E. Aranda-Flores
KTKIRVIS TORRES-POVEDA
KIRVIS TORRES-POVEDA
Background/Objectives: Cervical cancer (CC) is the fourth most common cancer among women worldwide. This study explored the use of machine learning (ML) and deep learning (DL) in the prediction, diagnosis, and prognosis of CC. Methods: An electronic search was conducted in the PubMed, IEEE, Web of Science, and Scopus databases from January 2015 to April 2025 using the search terms ML, DL, and uterine cervical neoplasms. A total of 153 studies were selected in this review. A comprehensive summary of the available evidence was compiled. Results: We found that 54.9% of the studies addressed the application of ML and DL in CC for diagnostic purposes, followed by prognosis (22.9%) and an incipient focus on CC treatment (22.2%). The five countries where most ML and DL applications have been generated are China, the United States, India, Republic of Korea, and Japan. Of these studies, 48.4% proposed a DL-based approach, and the most frequent input data used to train the models on CC were images. Conclusions: Although there are results indicating a promising application of these artificial intelligence approaches in oncology clinical practice, further evidence of their validity and reproducibility is required for their use in early detection, prognosis, and therapeutic management of CC.